PSY54 - BUDGET IMPACT ANALYSIS OF NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS IN TURKEY

Abstract

Idiopathic pulmonary fibrosis (IPF) is defined as a rare ( 11.5-26 cases per 100,000 person-years according to the European Respiratory Society) chronic, progressive, irreversible fibrosing interstitial pneumonia of unknown cause, occurring in adults. This analysis aims to assess the budget impact of nintedanib versus pirfenidone in the treatment of IPF for the Turkish Social Security Institution (SSI), and identify potential benefits of this new treatment entering the Turkish market. The study was undertaken from the payer’s perspective. Calculations estimated current and future expenses using official reimbursed prices in Turkey. Resource use data were obtained from the SSI official web site, the Turkish Medicines and Medical Devices Agency and national sales data. The population data were taken from TUIK 2017 statistics and the population growth rate was 12.4% simulated over 3 years prospectively. IPF prevalence was 0.020% Diagnosis rate for IPF patients was 54% and patient adherence was 62%. Nintedanib had been imported through the Turkish Pharmacists’ Association (TPA) until reimbursement, therefore TPA prices were applied in case of no reimbursement approval. Estimates showed that nintedanib could take 33.7% market shares from the overall IPF market for the first year, 43.0% for the second and 43.0% for the third year. According to our analysis, nintedanib’s entrance to the market could provide 5,441,698₺ savings in the first year on IPF drug expenditure including pirfenidone, 8,528,165₺ in the second and 9,053,578₺ in the third year, summing up to an overall saving of 23,023,441₺ over three years. Due to the significant unmet need for IPF patients in Turkey, the introduction of nintedanib could alleviate the associated economic burden for the SSI.